DBVT Earnings Prediction
The chart below shows how DBVT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DBVT sees a -2.38% change in stock price 10 days leading up to the earnings, and a -7.59% change 10 days following the report. On the earnings day itself, the stock moves by +4.32%. This data can give you a slight idea of what to expect for the next quarter's release.
DBVT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.16M
-49.26%
-17.48%
Gross Margin
--
--
--
Operating Margin
-2914.90%
165.96%
43.61%
Net Margin
-2852.37%
169.20%
47.28%
EPS
--
--
--
No Data Available
DBVT Earnings Analysis
DBV Technologies S.A. Corporation (DBVT.O) Earnings Conference Call
Positive
DBV Technologies extended their cash runway into Q1 of 2025 through continued cost-saving measures, showcasing effective financial management.
Cash on hand at the end of H1 was €66.2 million, with an extended cash runway compared to prior communication.
Cost-saving measures led to the extension of the cash runway.
DBV Technologies reported encouraging progress in their Viaskin Peanut development programs for children with peanut allergies, demonstrating commitment to addressing unmet medical needs.
Enrollment in the VITESSE Phase 3 trial for children aged four to seven is expected to be completed by the end of the third quarter.
Successful results from the EPITOPE Phase 3 efficacy study in toddlers one to three years old were achieved, meeting the primary endpoint.
Ongoing dialogue with the FDA regarding the COMFORT Toddlers supplemental safety study protocol shows dedication to regulatory compliance and patient safety.
DBV Technologies highlighted their financial efficiency and disciplined cash management in navigating operating expenses.
Operating income of $2.6 million, driven by research tax credit post-termination of a collaboration agreement.
Operating expenses of $65 million largely attributed to Viaskin Peanut clinical and CMC activities.
Net loss of $60.5 million reflects strategic investments and non-recurring expenses, indicating a focus on long-term growth.
Negative
**
- The company's cash runway has been extended into Q1 of 2025 due to cost-saving measures, indicating ongoing financial challenges and the need for continued efficiency in spending.
- DBV Technologies reported a net loss of $60.5 million for the first semester of 2024, driven by significant operating expenses related to clinical trials, CMC activities, and non-recurring costs like upfront study costs and supply chain activities.
- Cash used in operations totaled $70 million in the first semester of 2024, emphasizing the high costs associated with ongoing clinical trials, CMC, and regulatory activities, which could put strain on the company's financial resources and sustainability in the future.
DBVT FAQs
How does DBVT typically perform around its earnings report dates?
Is DBV Technologies S.A. (DBVT) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
DBVT Earning Call Sentiment
DBV Technologies S.A. (DBVT) Q2 2024 Earnings Call Transcript
1.0x
00:00
00:00
DBVT.O
1.84%Positive
The earnings call reveals mixed signals. The financial performance shows a net loss and increased expenses, but the cash runway extension is positive. Product development is progressing with regulatory engagement and trials, but risks remain. The Q&A highlights management's reluctance to provide clear data, which may concern investors. Overall, the sentiment is neutral, balancing financial challenges with strategic progress.